New drug hopes to tame rare muscle and skin disease

NCT ID NCT06284954

Ongoing Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called empasiprubart in adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. Three participants receive either the drug or a placebo for 25 weeks, then are followed for 65 more weeks. The goal is to see if the drug is safe and helps improve symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empasiprubart (also called ARGX-117), given as an intravenous infusion
What this could lead to: If it works, this could point toward a new treatment option for dermatomyositis, a rare autoimmune disease that causes muscle weakness and skin rash.
What could go wrong: This is a very early Phase 2 trial with only 3 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dermatomyositis juvenile dermatomyositis myositis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATOMYOSITIS MYOSITIS

Contacts and locations

Locations

Advance Medical Research Center

Miami, Florida, 33135, United States
Andreas Syggros Hospital of Skin and Venereal Diseases - University Dermatology and Venereology

Athens, 16121, Greece
Azienda Ospedaliera Universitaria Pisana

Pisa, 56126, Italy
D and H Tamarac Research, LLC Center

Tamarac, Florida, 33321, United States
Fondazione Policlinico Universitario Campus Bio-Medico

Rome, 00128, Italy
General Hospital of Thessaloniki Papageorgiou

Thessaloniki, 56429, Greece
Homestead Associates in Research, Inc.

Homestead, Florida, 33033, United States
Hospital Quironsalud Infanta Luisa

Seville, 41010, Spain
Hospital Universitario Rio Hortega

Valladolid, 47012, Spain
Institute of Cardiology

Chisinau, MD2025, Moldova
Institute of Clinical Cardiology, Ltd

Tbilisi, 0159, Georgia
Integral Rheumatology and Immunology Specialists (IRIS)

Plantation, Florida, 33324, United States
Jerarsi Clinic

Tbilisi, 0167, Georgia
Life Clinical Trials

Margate, Florida, 33063, United States
Mtskheta street Clinic

Tbilisi, 0179, Georgia
National and Kapodistrian University of Athens (NKUA) - University General Hospital Attikon

Athens, 12462, Greece
Nova Reuma Domyslawska i Rusilowicz- Spolka Partnerska Lekarza Reumatologa i Fizjoterapeuty

Bialystok, 15707, Poland
Omega Research Debary, LLC

DeBary, Florida, 32713, United States
Parc de Salut Mar - Hospital del Mar

Barcelona, 08003, Spain
Profound Research LLC

Oceanside, California, 92056, United States
Prywatna Praktyka Lekarska Prof. UM dr Hab. Med. Pawel Hrycaj

Poznan, 61-397, Poland
The First Medical Center

Tbilisi, 0180, Georgia
The First University Clinic of Tbilisi State Medical University

Tbilisi, 0141, Georgia
Timofei Mosneaga Republican Clinical Hospital

Chisinau, 2025, Moldova
University of Florida Health (UF) - Endocrinology - Medical Specialties - Medical Plaza

Gainesville, Florida, 32610, United States
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu

Wroclaw, 50-556, Poland
V.Tsitlanadze Scientific Practical Reumatology Center

Tbilisi, 0102, Georgia
Wright State Physicians Health Center

Dayton, Ohio, 45324, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.